Girolama A. Marfia

Is
Pozzilli, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 164 publications

Pregnancy Exposure to Anti-CD20 Monoclonal Antibodies in Patients With Multiple Sclerosis: Results From an Italian Multicenter Registry Study.

Pregnancy Exposure to Anti-CD20 Monoclonal Antibodies in Patients With Multiple Sclerosis: Results From an Italian Multicenter Registry Study.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: August 28, 2026

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 04, 2026

CSF Cytokine Network Organization Predicts Progression Independent of Relapse and MRI Activity in Multiple Sclerosis.

CSF Cytokine Network Organization Predicts Progression Independent of Relapse and MRI Activity in Multiple Sclerosis.

Journal: Annals of clinical and translational neurology

Published: May 21, 2026

Corrigendum to "Treatment discontinuation in older patients with multiple sclerosis" [Multiple Sclerosis and Related Disorders, Volume 103, November 2025, 106741].

Corrigendum to "Treatment discontinuation in older patients with multiple sclerosis" [Multiple Sclerosis and Related Disorders, Volume 103, November 2025, 106741].

Journal: Multiple sclerosis and related disorders

Published: May 14, 2026

Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosis.

Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosis.

Journal: The journal of headache and pain

Published: May 10, 2026

The impact of multiple sclerosis on social determinants of health: Results from the SocialMS study.

The impact of multiple sclerosis on social determinants of health: Results from the SocialMS study.

Journal: Multiple sclerosis and related disorders

Published: March 23, 2026

Subcutaneous natalizumab administration in relapsing-remitting multiple sclerosis: results of EASIER 2 study.

Subcutaneous natalizumab administration in relapsing-remitting multiple sclerosis: results of EASIER 2 study.

Journal: Journal of neurology

Published: March 19, 2026

Correction: Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis.

Correction: Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis.

Journal: Frontiers in neurology

Published: March 13, 2026

Web-based family-reported outcomes to assess family functioning in multiple sclerosis: an Italian multicenter digital survey.

Web-based family-reported outcomes to assess family functioning in multiple sclerosis: an Italian multicenter digital survey.

Journal: International journal of medical informatics

Published: January 25, 2026

Italian Delphi Consensus on Maternity Care in Multiple Sclerosis: Toward an Interdisciplinary Model of Care.

Italian Delphi Consensus on Maternity Care in Multiple Sclerosis: Toward an Interdisciplinary Model of Care.

Journal: European journal of neurology

Published: January 21, 2026

Inter-centre heterogeneity, temporal evolution, and factors associated with treatment selection and outcomes in chronic inflammatory demyelinating polyradiculoneuropathy: a multicentre, combined prospective and retrospective observational study.

Inter-centre heterogeneity, temporal evolution, and factors associated with treatment selection and outcomes in chronic inflammatory demyelinating polyradiculoneuropathy: a multicentre, combined prospective and retrospective observational study.

Journal: EClinicalMedicine

Published: January 14, 2026

Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis.

Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis.

Journal: Frontiers in neurology

Published: November 15, 2025

Showing 1-12 of 164

Last Updated: 09/26/2026